158 related articles for article (PubMed ID: 35934287)
1. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
2. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
3. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
Trauner M; Chung C; Sterling K; Liu X; Lu X; Xu J; Tempany-Afdhal C; Goodman ZD; Färkkilä M; Tanaka A; Trivedi P; Kowdley KV; Bowlus CL; Levy C; Myers RP
BMC Gastroenterol; 2023 Mar; 23(1):75. PubMed ID: 36922785
[TBL] [Abstract][Full Text] [Related]
4. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
7. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
[TBL] [Abstract][Full Text] [Related]
10. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
12. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
14. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
15. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
16. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN
Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
Gilger MA; Gann ME; Opekun AR; Gleason WA
J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
[TBL] [Abstract][Full Text] [Related]
19. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid for primary sclerosing cholangitis.
Chazouillères O; Poupon R; Capron JP; Metman EH; Dhumeaux D; Amouretti M; Couzigou P; Labayle D; Trinchet JC
J Hepatol; 1990 Jul; 11(1):120-3. PubMed ID: 1975818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]